Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response

TLR7 agonists are considered promising drugs for cancer therapy. The currently available compounds are not well tolerated when administered intravenously and therefore are restricted to disease settings amenable for topical application. Here we present the preclinical characterization of SC1, a nove...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Vascotto, Fulvia, Petschenka, Jutta, Walzer, Kerstin C., Vormehr, Mathias, Brkic, Magdalena, Strobl, Stefan, Rösemann, Roman, Diken, Mustafa, Kreiter, Sebastian, Türeci, Özlem, Sahin, Ugur
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2019
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6527305/
https://ncbi.nlm.nih.gov/pubmed/31143525
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2019.1601480
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados